|
the |
|
initiative |
|
ReLeef |
|
Program Overview |


|
Four Basic Principles |
|
Our Program
|
|
Principle 1: To develop a product with extreme safety. The organization is planning to develop a product consisting of active ingredients with uncompromised long-standing safety documentation.
Principle 2: To develop a product that can be manufactured at a very low cost. The active ingredients will be manufactured via standard process chemistry. Our delivery technology will involve safe excipients, which are also very inexpensive to manufacture. |
|
Principle 3: To develop a product that is compatible with pediatric use. The organization is developing intellectual property around novel packaging formats combined with a new mini-particle technology that allows flexible dosing, taste-free coating and provides extended release compatible with a single daily dose administration.
Principle 4: To make the program self-sustainable through licensing agreements with for-profit industry. Releef is planning to out-license the rights to sell products based on our intellectual property to for-profit partners. The partners will have rights to manufacture, distribute, and sell products in developed countries. In return, Releef will obtain a royalty stream that can be used for purchase of product for humanitarian use. We believe that for-profit mechanisms are the best way to ensure sustainability. |
|
Program |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
|
Tissue wasting in infectious diseases and cancer |
|
|
|
|
|
|
|
|
Formulation and dispensing technology for pediatric drugs |
|
|
|
|
|
|
|
|
|
Pre-clinical development |
|
|
Clinical development |
|
Copyright © 2005-2009 The Releef Initiative - All rights reserved The Releef Initiative is an IRS 501(c)3 nonprofit charitable organization |